Identifying Current Barriers and Optimization Opportunities of Rapid Access Pathway to Outpatient Care for High-Cost Biologics in an Academic Health System

Authors

Avani Topiwala PharmD, Yale New Haven Health/Bridgeport Hospital
Vincent Do PharmD, BCPS, BCTXP, Yale New Haven Health/Bridgeport Hospital
Joseph Rosano BS, PharmD, Yale New Haven Health/Bridgeport Hospital

Document Type

Conference Proceeding

Abstract

• Inpatient administration of specialty biologic agents can have significant financial impacts on a healthcare system.
• The “Never Administer Inpatient List” (NAIL) is an established reference which contains biologic infusions that should be administered in an outpatient setting when clinically appropriate.
• While outpatient administration may be clinically appropriate, there are many barriers to coordinating outpatient infusions that result in unnecessary inpatient administration. This can result in a prolonged length of stay and increased medication cost.

Publication Date

12-2024

Comments

Presented at the 59th Annual ASHP Midyear Clinical Meeting, December 9-12, 2024. Disclosure: The authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Avani Topiwala: Nothing to disclose, Vincent Do: Nothing to disclose, Joseph Rosano: Nothing to disclose

Recommended Citation

Topiwala, Avani PharmD; Do, Vincent PharmD, BCPS, BCTXP; and Rosano, Joseph BS, PharmD, "Identifying Current Barriers and Optimization Opportunities of Rapid Access Pathway to Outpatient Care for High-Cost Biologics in an Academic Health System" (2024). Posters. 20.
https://scholar.bridgeporthospital.org/poster_presentations/20